Andrew E. Singer was appointed Director of Kyntra Bio, Inc., effective October 1, 2026. As of November 4, 2026, Kyntra Bio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 1, 2026, naming 1 appointment (Form 8-K, October 1, 2026).
Sell to companies like Kyntra Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kyntra Bio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-01. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Kyntra Bio, Inc. files it.
Also on the record for Kyntra Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.88% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.88% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.89% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.35% of the class | 5%+ stakes | Source |
| August 15, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 8.31% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kyntra Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Kyntra Bio, Inc. and the records around it.
Kyntra Bio, Inc. elsewhere on the record
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- The Vanguard Group also filed stake reports on 2383 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Kyntra Bio, Inc.
Get an email when Kyntra Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kyntra Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kyntra Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kyntra Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-01 | In | Director | 2026-10-01 | 8-K, 2026-10-01 |
Who leads Kyntra Bio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Andrew E. Singer, appointed, effective 2026-10-01 (filed 2026-10-01).
New leaders reset buying decisions — get the Full Report on Kyntra Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Kyntra Bio, Inc., with the record behind each one.
Find candidates like Director at Kyntra Bio, Inc.Every change, in the filing's words
Appointed: Andrew E. Singer, Director, effective 2026-10-01
Director Appointment Effective October 1, 2026, the Board of Directors (the "Board") of the Kyntra Bio, Inc. (the "Company" or "Kyntra Bio") appointed Andrew E. Singer, MBA as a Class III director of the Company.
- Mr. Singer was also appointed to the Audit Committee of the Board.
- Kyntra Bio is delighted to welcome Mr. Singer to the Board.
- Mr. Singer's biopharma related investment banking, strategic and transactions expertise will bring a valuable perspective to the Company as Kyntra Bio focuses on the development of novel therapies in oncology and rare disease.
- Mr. Singer will hold office for the term expiring 2029.
- Mr. Singer will receive compensation as a non-employee director of the Company as approved by the Board under the Company's Non-Employee Director Compensation Policy, as amended and approved by the Board on April 10, 2026.
- Dr. Ho's resignation as director is not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies, or practices.
- Dr. Ho joined the Company's Board in December 2018 and served in a number of capacities during her tenure with the Company, including as a member of the Audit Committee.
- Dr. Ho's financial expertise was instrumental throughout her tenure, including as the Company achieved regulatory approval outside of the United States and commercially launched roxadustat in international markets, including the People's Republic of China.
- The Company is extremely grateful for the valuable guidance and direction Dr. Ho provided over the years and extends its best wishes for her future endeavors.
Tools for this story
Each opens in a new tab, filled in for Kyntra Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.